Zimmer Biomet Holdings Inc. (ZBH) financial statements: income statement, balance sheet and cash flow
Zimmer Biomet Holdings Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Zimmer Biomet Holdings Inc. reported revenue of $8.2B (+7.2% year on year) and net income of $705.1M (-22.1% year on year).
Income statement
Zimmer Biomet Holdings Inc. income statement, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Net Sales
$8.2B
$7.7B
$7.4B
$6.9B
Cost of products sold, excluding intangible asset amortization
$2.5B
$2.2B
$2.1B
$2.0B
Intangible asset amortization
$665.9M
$591.9M
$561.5M
$526.8M
Research and development
$458.5M
$437.4M
$458.7M
$406.0M
Selling, general and administrative
$3.3B
$2.9B
$2.8B
$2.8B
Restructuring and other cost reduction initiatives
$181.2M
$219.0M
$151.9M
$191.6M
Acquisition, integration, divestiture and related
$76.9M
$23.6M
$21.7M
$11.4M
Operating expenses
$7.1B
$6.4B
$6.1B
$6.2B
Operating Profit
$1.1B
$1.3B
$1.3B
$696.3M
Other income (expense), net
$25.5M
($31.1M)
($9.3M)
($128.0M)
Interest expense, net
($292.8M)
($218.0M)
($201.2M)
($164.8M)
Earnings before income taxes
$830.8M
$1.0B
$1.1B
$403.5M
Provision for income taxes
$125.7M
$131.4M
$42.2M
$112.3M
Net Earnings
$705.1M
$905.2M
$1.0B
$291.2M
Less: Net (loss) earnings attributable to noncontrolling interest
($100.0K)
$1.5M
$1.1M
$1.0M
Net Earnings of Zimmer Biomet Holdings, Inc.
$705.1M
$903.8M
$1.0B
$231.4M
Basic
$3.56
$4.45
$4.91
$1.10
Diluted
$3.55
$4.43
$4.88
$1.10
Basic
198.0M
203.1M
208.7M
209.6M
Diluted
198.7M
203.9M
209.7M
210.3M
Zimmer Biomet Holdings Inc. income statement, quarters
Line item
Jun 30, 2026 · Q2
Mar 31, 2026 · Q1
Sep 30, 2025 · Q3
Jun 30, 2025 · Q2
Net Sales
$2.2B
$2.1B
$2.0B
$2.1B
Cost of products sold, excluding intangible asset amortization
$635.5M
$576.2M
$559.3M
$592.2M
Intangible asset amortization
$163.4M
$162.1M
$176.5M
$160.6M
Research and development
$104.8M
$103.4M
$115.9M
$113.3M
Selling, general and administrative
$899.3M
$849.9M
$811.4M
$814.8M
Restructuring and other cost reduction initiatives
$29.8M
$6.3M
$21.4M
$17.5M
Acquisition, integration, divestiture and related
$18.1M
$15.6M
($34.4M)
$78.9M
Operating expenses
$1.9B
$1.7B
$1.7B
$1.8B
Operating Profit
$326.1M
$373.2M
$351.3M
$300.0M
Other income (expense), net
$1.9M
($3.0M)
$3.3M
$3.9M
Interest expense, net
($72.9M)
($68.8M)
($75.4M)
($79.3M)
Earnings before income taxes
$255.1M
$301.3M
$279.2M
$224.6M
Provision for income taxes
$55.5M
$63.0M
$48.0M
$71.2M
Net Earnings
$199.6M
$238.3M
$231.2M
$153.4M
Less: Net earnings attributable to noncontrolling interest
$1.3M
$200.0K
$300.0K
$600.0K
Net Earnings of Zimmer Biomet Holdings, Inc.
$198.3M
$238.1M
$230.9M
$152.8M
Basic
$1.03
$1.22
$1.17
$0.77
Diluted
$1.03
$1.22
$1.16
$0.77
Basic
192.2M
195.0M
198.1M
197.9M
Diluted
192.8M
195.8M
198.8M
198.3M
Balance sheet
Zimmer Biomet Holdings Inc. balance sheet, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Cash and cash equivalents
$591.9M
$525.5M
$415.8M
$375.7M
Accounts receivable, less allowance for credit losses
$1.7B
$1.5B
$1.4B
$1.4B
Inventories
$2.3B
$2.2B
$2.4B
$2.1B
Prepaid expenses and other current assets
$537.3M
$430.1M
$366.1M
$324.5M
Total Current Assets
$5.1B
$4.7B
$4.6B
$4.4B
Property, plant and equipment, net
$2.2B
$2.0B
$2.1B
$1.9B
Goodwill
$9.9B
$9.0B
$8.8B
$8.6B
Intangible assets, net
$4.7B
$4.6B
$4.9B
$5.1B
Other assets
$1.1B
$1.1B
$1.2B
$1.1B
Total Assets
$23.1B
$21.4B
$21.5B
$21.1B
Accounts payable
$303.0M
$194.6M
$410.6M
$354.1M
Other current liabilities
$1.7B
$1.4B
$1.5B
$1.4B
Current portion of long-term debt
$587.1M
$863.0M
$900.0M
$544.3M
Total Current Liabilities
$2.6B
$2.5B
$2.9B
$2.4B
Deferred income taxes, net
$244.1M
$352.5M
$357.6M
$474.8M
Other long-term liabilities
$626.1M
$744.1M
$652.1M
$632.6M
Long-term debt
$6.9B
$5.3B
$4.9B
$5.2B
Total Liabilities
$10.4B
$8.9B
$9.0B
$9.0B
Common stock, $0.01 par value, one billion shares authorized, 318.7 million (317.5 million in 2024) issued
3.2M
3.2M
3.2M
3.1M
Paid-in capital
$10.2B
$10.0B
$9.8B
$9.5B
Retained earnings
$11.6B
$11.1B
$10.4B
$9.6B
Accumulated other comprehensive loss
($205.7M)
($262.8M)
($191.0M)
($179.3M)
Treasury stock, 123.2 million shares (118.4 million shares in 2024)
-8.9B
-8.4B
-7.6B
-6.9B
Total Zimmer Biomet Holdings, Inc. stockholders' equity
$12.7B
$12.5B
$12.5B
$12.0B
Noncontrolling interest
$8.1M
$8.1M
$7.7M
$6.7M
Total Stockholders' Equity
$12.7B
$12.5B
$12.5B
$12.0B
Total Liabilities and Stockholders' Equity
$23.1B
$21.4B
$21.5B
$21.1B
Zimmer Biomet Holdings Inc. balance sheet, quarters
Line item
Jun 30, 2026
Mar 31, 2026
Sep 30, 2025
Jun 30, 2025
Cash and cash equivalents
$410.0M
$424.2M
$1.3B
$556.9M
Accounts receivable, less allowance for credit losses
$1.8B
$1.7B
$1.6B
$1.6B
Inventories
$2.3B
$2.2B
$2.5B
$2.5B
Prepaid expenses and other current assets
$646.9M
$562.9M
$460.3M
$431.4M
Total Current Assets
$5.1B
$5.0B
$5.8B
$5.1B
Property, plant and equipment, net
$2.2B
$2.2B
$2.2B
$2.2B
Goodwill
$9.9B
$9.9B
$9.7B
$9.7B
Intangible assets, net
$4.5B
$4.5B
$4.7B
$4.9B
Other assets
$1.1B
$1.1B
$1.0B
$1.0B
Total Assets
$22.8B
$22.7B
$23.5B
$22.9B
Accounts payable
$352.4M
$361.2M
$315.3M
$348.7M
Salaries, wages and benefits
$334.3M
$293.9M
—
—
Other current liabilities
$1.1B
$1.0B
$1.5B
$1.5B
Current portion of long-term debt
$1.2B
$1.2B
$600.0M
$820.0M
Total Current Liabilities
$3.0B
$2.9B
$2.4B
$2.7B
Deferred income taxes, net
$235.6M
$249.9M
—
—
Other long-term liabilities
$638.7M
$630.7M
$806.4M
$878.8M
Long-term debt
$6.3B
$6.3B
$7.5B
$6.8B
Total Liabilities
$10.2B
$10.0B
$10.7B
$10.3B
Common stock, $0.01 par value, one billion shares authorized, 319.4 million shares as of June 30, 2026 (318.7 million as of December 31, 2025) issued
3.2M
3.2M
3.2M
3.2M
Paid-in capital
$10.2B
$10.2B
$10.2B
$10.1B
Retained earnings
$12.0B
$11.8B
$11.5B
$11.3B
Accumulated other comprehensive loss
($163.9M)
($190.4M)
($283.8M)
($284.5M)
Treasury stock, 128.8 million shares as of June 30, 2026 (123.2 million as of December 31, 2025)
-9.4B
-9.1B
-8.6B
-8.6B
Total Zimmer Biomet Holdings, Inc. stockholders' equity
$12.6B
$12.7B
$12.8B
$12.5B
Noncontrolling interest
$8.7M
$8.2M
$9.5M
$9.3M
Total Stockholders' Equity
$12.6B
$12.7B
$12.8B
$12.5B
Total Liabilities and Stockholders' Equity
$22.8B
$22.7B
$23.5B
$22.9B
Cash flow statement
Zimmer Biomet Holdings Inc. cash flow statement, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Net earnings
$705.1M
$905.2M
$1.0B
$291.2M
Depreciation and amortization
$1.1B
$996.3M
$951.7M
$926.4M
Share-based compensation
$90.2M
$101.0M
$99.8M
$105.0M
Deferred income tax benefit
($87.2M)
($47.7M)
($96.3M)
($64.4M)
Income taxes
($166.6M)
($158.6M)
($73.8M)
($152.9M)
Receivables
($127.3M)
($89.7M)
($51.9M)
($184.7M)
Inventories
$98.2M
$49.9M
($240.4M)
($75.6M)
Accounts payable and accrued liabilities
$101.8M
($322.0M)
($55.3M)
$103.0M
Other assets and liabilities
($11.0M)
$65.0M
$25.2M
($1.2M)
Net cash provided by operating activities
$1.7B
—
—
—
Additions to instruments
($300.5M)
($240.3M)
($311.7M)
($258.3M)
Additions to other property, plant and equipment
($224.5M)
($203.8M)
($291.1M)
($187.9M)
Net investment hedge settlements
($400.0K)
$22.1M
$33.4M
$89.4M
Acquisition of intangible assets
($52.4M)
($153.0M)
($86.4M)
—
Business combination investments, net of acquired cash
($1.4B)
($276.3M)
($134.9M)
($99.8M)
Other investing activities
($4.6M)
($36.9M)
$11.8M
($65.4M)
Net cash used in investing activities
($2.0B)
$0
$0
($7.2M)
Proceeds from senior notes
$2.5B
$1.4B
$499.8M
—
Redemption of senior notes
($1.5B)
($850.0M)
($86.3M)
($1.3B)
Dividends paid to stockholders
($190.3M)
($196.0M)
($200.9M)
($201.2M)
Proceeds from employee stock compensation plans
39.7M
82.1M
101.1M
78.1M
Business combination contingent consideration payments
($25.0M)
($3.5M)
($10.3M)
—
Debt issuance costs
($22.7M)
($13.0M)
($5.8M)
($1.6M)
Repurchase of common stock
($487.0M)
($868.0M)
($692.2M)
($126.4M)
Other financing activities
($17.7M)
($22.4M)
($6.1M)
($4.5M)
Net cash provided by (used in) financing activities
$326.0M
—
—
—
Effect of exchange rates on cash and cash equivalents
$19.0M
($17.1M)
$900.0K
($14.5M)
Increase in cash and cash equivalents
$66.4M
$109.7M
$40.1M
($102.8M)
Cash and cash equivalents, beginning of year
$525.5M
$415.8M
$375.7M
$478.5M
Cash and cash equivalents, end of year
$591.9M
$525.5M
—
—
Zimmer Biomet Holdings Inc. cash flow statement, quarters
Line item
Jun 30, 2026 · YTD
Mar 31, 2026 · Q1
Sep 30, 2025 · YTD
Jun 30, 2025 · YTD
Net earnings
$437.9M
$238.3M
$567.2M
$336.0M
Depreciation and amortization
$540.8M
$270.0M
$809.8M
$526.2M
Share-based compensation
$48.8M
$24.2M
$66.1M
$40.8M
Income taxes
($80.1M)
($7.4M)
($174.7M)
($132.0M)
Receivables
($24.0M)
$14.5M
($15.6M)
($18.6M)
Inventories
($51.4M)
($20.9M)
($86.2M)
($40.2M)
Accounts payable and accrued liabilities
($91.0M)
($183.0M)
($11.1M)
$40.4M
Other assets and liabilities
$26.1M
$23.5M
$24.1M
$8.3M
Net cash provided by operating activities
$807.2M
$359.4M
$1.2B
$761.0M
Additions to instruments
($162.6M)
($77.2M)
($226.2M)
($140.2M)
Additions to other property, plant and equipment
($90.5M)
($36.3M)
($149.7M)
($94.7M)
Net investment hedge settlements
$10.8M
($300.0K)
($5.3M)
$3.5M
Acquisition of intangible assets
($101.2M)
($39.0M)
($42.4M)
($32.4M)
Other investing activities
($6.3M)
($6.2M)
($3.8M)
($300.0K)
Net cash used in investing activities
($349.8M)
($159.0M)
($1.7B)
($1.5B)
Net proceeds from revolving facilities
$30.0M
—
—
$220.0M
Dividends paid to stockholders
($93.4M)
($46.9M)
($142.8M)
($95.3M)
Proceeds from employee stock compensation plans
12.4M
12.3M
38.0M
17.1M
Business combination contingent consideration payments
($69.2M)
($69.0M)
($25.0M)
($17.4M)
Debt issuance costs
($1.3M)
—
($22.7M)
($17.3M)
Repurchase of common stock
($500.8M)
($250.1M)
($237.0M)
($237.0M)
Other financing activities
($17.9M)
($15.6M)
($16.6M)
($16.1M)
Net cash (used in) provided by financing activities
($640.3M)
($369.2M)
$1.2B
$739.2M
Effect of exchange rates on cash and cash equivalents